An important message from NCRVA regarding coronavirus (COVID-19).

COVID-19 & Your Appointment
Northern California Retina Vitreous Associates logo for print
  • Daly City: 650-994-2100
  • San Mateo: 650-340-0111
  • Mountain View: 650-963-3460
  • Monterey: 831-373-6280
  • East San Jose: 408-251-3500
  • West San Jose: 408-356-8818
Reset Text size:
Reset Text size:

Clinical Trials

Dry Age Related Macular Degeneration

Active Studies

ARCHER (Annexon)

A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

CATALINA (NGM Biopharmaceuticals)

A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).

DERBY (Apellis)

A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

GALLEGO (Genentech)

A 18-month, phase II, multicenter, randomized, single-masked, sham-controlled study to assess safety, tolerability, and efficacy of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration.

GR42163 (Genentech)

A PHASE Ia, MULTICENTER, OPEN-LABEL, SINGLE-DOSE, DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF INTRAVITREAL INJECTIONS OF RO7303359 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.


Completed Studies

BEACON (Allergan)

A 2 year, phase 2 study on the safety and efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with geography atrophy secondary to age-related macular degeneration.

GATHER 2 (Iveric)

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA™ (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION.

GR39821 (Genentech)

A phase 1, open-label, single-dose, dose-escalation, and multiple-dose study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FHTR2163 in patients with geographic atrophy secondary to macular degeneration.

ICON (Pfizer)

A 1 year Phase 2 study examining a monoclonal antibody to decrease the amount of drusen in the eyes seen in people with Dry AMD with an intravenous infusion.

OMASPECT (Genentech)

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a roche-sponsored study.

PREVENT IIT (NCRVA & Genentech)

A 2 year investigator initiated study on prophylactic Ranibizumab for exudative age-related macular degeneration (AMD) in vulnerable eyes with Non exudative AMD Trial.

SEATTLE (Acucela)

A 2 year Phase 2/3 study which aims to reduce the rate of Dry AMD progression with the use of an pill.

SPECTRI (Genentech)

A 2 year, phase 3, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of Lampalizumab administered intravitreally to patients with Geographic Atrophy secondary to Age-Related Macular Degeneration.

TARGETing GA (Santen Inc.)

Non-interventional, cross-sectional study of Alu RNA measurement and complement factor genotyping of single nucleotide polymorphisms in the complement pathway in patients with geographic atrophy associated with dry age-related macular degeneration.

ZIMURA (Ophthotech)

A 18-month, phase2B study on the safety and efficacy of Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.